温和灸治疗腹泻型肠易激综合征的随机对照试验
本研究为单中心随机对照试验,纳入76例符合罗马IV诊断标准的腹泻型肠易激综合征(IBS-D)患者,按1:1随机分为温和灸组与安慰灸组,每组38例,每周治疗3次共6周(18次)。主要结局为治疗6周后的充分缓解率,温和灸组显著高于安慰灸组(81.58% vs. 36.84%),估计差值44.74(95% CI 23.46至66.02,P<0.001),未见严重不良事件,疗效可持续至12周。
要点
- 温和灸治疗6周后IBS-D充分缓解率显著优于安慰灸。
- 疗效可持续至治疗后12周,且未报告严重不良事件。
- 结果为单中心随机对照试验,需多中心验证。
核心结论
- 温和灸可能比安慰灸更有效地治疗腹泻型肠易激综合征,疗效可持续至12周。
研究设计与样本
- 单中心随机对照试验,于中国上海针灸经络研究所开展,2017年5月至2019年12月纳入76例符合罗马IV诊断标准的IBS-D患者,按1:1随机分为温和灸组(38例)和安慰灸组(38例),共治疗6周18次(每周3次),采用意向性分析。
主要发现
- 治疗6周后,温和灸组充分缓解率为81.58%,安慰灸组为36.84%,估计差值44.74(95% CI 23.46至66.02,P<0.001)。
- 未报告严重不良事件。
- 疗效可持续至12周。
关键数值与推荐
- 主要结局为治疗6周后的充分缓解率,温和灸组81.58% vs. 安慰灸组36.84%,差值44.74(95% CI 23.46至66.02,P<0.001)。
临床怎么用
- 对于符合罗马IV诊断标准的IBS-D患者,可考虑采用温和灸治疗,每周3次共6周,可能获得较高的充分缓解率且安全性较好。
局限性
- 单中心研究,样本量较小(76例),结果需多中心大样本试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Moxibustion therapy is a traditional Chinese medicine external treatment method, which involves crushing dried herb Artemisia argyi H. Lév. & Vanio and rolling it into a long cigarette-like strip, igniting it and using its warmth to stimulate specific acupuncture points for a certain period of time. It is often used in Asia to treat various diseases, especially abdominal pain. Clinical reports suggest that acupuncture and moxibustion are the effective treatment for Irritable Bowel Syndrome with Diarrhea (IBS-D). However, there is no placebo-controlled study to prove its safety and efficacy. OBJECTIVE: To evaluate the effects of mild moxibustion (MM) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) through comparisons with those of placebo moxibustion. PATIENTS AND METHODS: This was a single-site, randomized controlled trial was conducted at Shanghai Research Institute of Acupuncture and Meridian in China and enrolled 76 participants who met the Rome IV diagnostic criteria for IBS-D between May 2017 and December 2019. 76 participants were randomized to either mild moxibustion (MM) or placebo moxibustion group (PM) in a 1:1 ratio. 18 sessions of MM or PM were implemented over the course of 6 weeks (3 times per week). The primary outcome was adequate relief after 6 weeks of treatment. RESULTS: Of 76 patients with IBS-D who were randomized (38 in the MM group and 38 in the PM group) were included in the intention-to-treat (ITT) analysis set. After treatment at week 6, the response rate was significantly higher in the MM group than the PM group (81.58% vs. 36.84%) with an estimated difference of 44.74 (95% CI, 23.46 to 66.02, P < 0.001). No participant reported severe adverse effects. CONCLUSION: The findings suggest that mild moxibustion may be more effective than placebo moxibustion for the treatment of IBS-D, with effects lasting up to 12 weeks. TRIAL REGISTRATION: ChiCTR, ChiCTR2100046852. Registered 29 May 2021 - Retrospectively registered, URL: http://www.chictr.org.cn/showproj.aspx?proj=127000.
引用
- Wang Z, Xu M, Shi Z, et al. Mild moxibustion for Irritable Bowel Syndrome with Diarrhea (IBS-D): A randomized controlled trial. J Ethnopharmacol. 2022. PMID: 35114338. doi:10.1016/j.jep.2022.115064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。